Rosuvastatin decreases caveolin-1 and improves nitric oxide-dependent heart rate and blood pressure variability in apolipoprotein E-/- mice in vivo

Circulation

Volumn 107, Issue 19, 2003, Pages 2480-2486

  Pelat, Michel ^b   Dessy, Chantal ^b   Massion, Paul ^b   Desager, Jean Pierre ^b   Feron, Olivier ^b   Balligand, Jean Luc ^a  

^a UNIVERSITÉ CATHOLIQUE DE LOUVAIN   (Belgium)

^b NONE

Author keywords

Blood pressure; Cholesterol; Nervous system, autonomic; Nitric oxide; Rosuvastatin

Indexed keywords

APOLIPOPROTEIN E; ATROPINE; CAVEOLIN 1; LIPID; N(G) NITROARGININE METHYL ESTER; NITRIC OXIDE; NITRIC OXIDE SYNTHASE INHIBITOR; PLACEBO; ROSUVASTATIN;

ANIMAL CELL; ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; AORTA MEDIA; ARTICLE; AUTONOMIC DYSFUNCTION; BLOOD PRESSURE MEASUREMENT; CARDIOVASCULAR DISEASE; CIRCADIAN RHYTHM; CONTROLLED STUDY; CORRELATION ANALYSIS; DOSE TIME EFFECT RELATION; DRUG MECHANISM; DYSLIPIDEMIA; ENDOTHELIUM INJURY; ENZYME MODIFICATION; FREQUENCY ANALYSIS; HEART RATE VARIABILITY; HEMODYNAMIC MONITORING; HUMORAL IMMUNITY; IMMUNOBLOTTING; LONG TERM EXPOSURE; MALE; MOUSE; MUSCLE TISSUE; NONHUMAN; OXIDATIVE STRESS; PRIORITY JOURNAL; PROGNOSIS; PROTEIN EXPRESSION; SENSITIVITY ANALYSIS; SPATIAL ORIENTATION; SYSTOLIC BLOOD PRESSURE; TELEMETRY;

ANIMALS; AORTA; APOLIPOPROTEINS E; AUTONOMIC NERVOUS SYSTEM; BLOOD PRESSURE; BLOOD PRESSURE MONITORING, AMBULATORY; CAVEOLIN 1; CAVEOLINS; CHOLESTEROL; CHRONOBIOLOGY DISORDERS; ELECTROCARDIOGRAPHY, AMBULATORY; FLUOROBENZENES; HEART RATE; HYPERLIPIDEMIAS; MICE; MICE, INBRED C57BL; MICE, KNOCKOUT; MYOCARDIUM; NITRIC OXIDE; NITRIC OXIDE SYNTHASE; NITRIC OXIDE SYNTHASE TYPE II; NITRIC OXIDE SYNTHASE TYPE III; PYRIMIDINES; SULFONAMIDES; TREATMENT OUTCOME;

EID: 0038179586     PISSN: 00097322     EISSN: None     Source Type: Journal    
DOI: 10.1161/01.CIR.0000065601.83526.3E     Document Type: Article

References (41)

1. Nazzaro P, Manzari M, Merlo M, et al. Distinct and combined vascular effects of ACE blockade and HMG-CoA reductase inhibition in hypertensive subjects. Hypertension. 1999;33:719-725.
2. Pehlivanidis AN, Athyros VG, Demitriadis DS, et al. Heart rate variability after long-term treatment with atorvastatin in hypercholesterolaemic patients with or without coronary artery disease. Atherosclerosis. 2001;157:463-469.
3. Huikuri HV, Jokinen V, Syvanne M, et al. Heart rate variability and progression of coronary atherosclerosis. Arterioscler Thromb Vasc Biol. 1999; 19:1979-1985.
4. Sega R, Corrao G, Bombelli M, et al. Blood pressure variability and organ damage in a general population: results from the PAMELA study (Pressioni Arteriose Monitorate E Loro Associazioni). Hypertension. 2002;39:710-714.
5. Mancia G, Frattola A, Parati G, et al. Blood pressure variability and organ damage. J Cardiovasc Pharmacol. 1994;24(suppl A):S6-S11.
6. Stauss HM, Persson PB. Role of nitric oxide in buffering short-term blood pressure fluctuations. News Physiol Sci. 2000;15:229-233.
7. Huang PL, Huang Z, Mashimo H, et al. Hypertension in mice lacking the gene for endothelial nitric oxide synthase. Nature. 1995;377:239-242.
8. Shesely EG, Maeda N, Kim HS, et al. Elevated blood pressures in mice lacking endothelial nitric oxide synthase. Proc Natl Acad Sci USA. 1996; 93:13176-13181.
9. Stauss HM, Nafz B, Mrowka R, et al. Blood pressure control in eNOS knock-out mice: comparison with other species under NO blockade. Acta Physiol Scand. 2000;168:155-160.
10. Stauss HM, Godecke A, Mrowka R, et al. Enhanced blood pressure variability in eNOS knockout mice. Hypertension. 1999;33:1359-1363.
11. Barton M, Haudenschild CC, d'Uscio LV, et al. Endothelin ETA receptor blockade restores NO-mediated endothelial function and inhibits atherosclerosis in apolipoprotein E-deficient mice. Proc Natl Acad Sci U S A. 1998;95: 14367-14372.
12. Feron O, Dessy C, Moniotte S, et al. Hypercholesterolemia decreases nitric oxide production by promoting the interaction of caveolin and endothelial nitric oxide synthase. J Clin Invest. 1999;103:897-905.
13. Fulton D, Gratton JP, Sessa WC. Post-translational control of endothelial nitric oxide synthase: why isn't calcium/calmodulin enough? J Pharmacol Exp Ther. 2001;299:818-824.
14. Just A, Faulhaber J, Ehmke H. Autonomic cardiovascular control in conscious mice. Am J Physiol. 2000;279:R2214-R2221.
15. Feron O, Dessy C, Desager JP, et al. Hydroxy-methylglutaryl-coenzyme A reductase inhibition promotes endothelial nitric oxide synthase activation through a decrease in caveolin abundance. Circulation. 2001:103:113-118.
16. Brouet A, Sonveaux P, Dessy C, et al. Hsp90 and caveolin are key targets for the proangiogenic nitric oxide-mediated effects of statins. Circ Res. 2001; 89:866-873.
17. 2-cholinoceptor function in obesity-related hypertension. Hypertension. 1999;34:1066-1072.
18. Makino M, Hayashi H, Takezawa H, et al. Circadian rhythms of cardiovascular functions are modulated by the baroreflex and the autonomic nervous system in the rat. Circulation. 1997;96:1667-1674.
19. Herring N, Paterson DJ. Nitric oxide-cGMP pathway facilitates acetylcholine release and bradycardia during vagal nerve stimulation in the guinea-pig in vitro. J Physiol. 2001;535:507-518.
20. Balligand JL, Kelly RA, Marsden PA, et al. Control of cardiac muscle cell function by an endogenous nitric oxide signaling system. Proc Natl Acad Sci USA. 1993;90:347-351.
21. Balligand JL, Kobzik L, Han X, et al. Nitric oxide-dependent parasympathetic signaling is due to activation of constitutive endothelial (type III) nitric oxide synthase in cardiac myocytes. J Biol Chem. 1995;270:14582-14586.
22. Han X, Shimoni Y, Giles WR. A cellular mechanism for nitric oxidemediated cholinergic control of mammalian heart rate. J Gen Physiol. 1995; 106:45-65.
23. Laufs U, Liao JK. Direct vascular effects of HMG-CoA reductase inhibitors. Trends Cardiovasc Med. 2000;10:143-148.
24. Wassmann S, Laufs U, Muller K, et al. Cellular antioxidant effects of atorvastatin in vitro and in vivo. Arterioscler Thromb Vasc Biol. 2002;22: 300-305.
25. Bonthu S, Heistad DD, Chappell DA, et al. Atherosclerosis, vascular remodeling, and impairment of endothelium-dependent relaxation in genetically altered hyperlipidemic mice. Arterioscler Thromb Vasc Biol. 1997;17: 2333-2340.
26. Yang R, Powell-Braxton L, Ogaoawara AK, et al. Hypertension and endothelial dysfunction in apolipoprotein E knockout mice. Arterioscler Thromb Vasc Biol. 1999;19:2762-2768.
27. Kajekar R, Moore PK, Brain SD. Essential role for nitric oxide in neurogenic inflammation in rat cutaneous microcirculation: evidence for an endothelium-independent mechanism. Circ Res. 1995;76:441-447.
28. Butz GM, Davisson RL. Long-term telemetric measurement of cardiovascular parameters in awake mice: a physiological genomics tool. Physiol Genomics. 2001;5:89-97.
29. Feron O, Saldana F, Michel JB, et al. The endothelial nitric-oxide synthasecaveolin regulatory cycle. J Biol Chem. 1998:273:3125-3128.
30. Razani B, Engelman JA, Wang XB, et al. Caveolin-1 null mice are viable but show evidence of hyperproliferative and vascular abnormalities. J Biol Chem. 2001;276:38121-38138.
31. Drab M, Verkade P, Elger M, et al. Loss of caveolae, vascular dysfunction, and pulmonary defects in caveolin-1 gene-disrupted mice. Science. 2001;293: 2449-2452.
32. Liao JK, Shin WS, Lee WY, et al. Oxidized low-density lipoprotein decreases the expression of endothelial nitric oxide synthase. J Biol Chem. 1995;270: 319-324.
33. Blair A, Shaul PW, Yuhanna IS, et al. Oxidized low density lipoprotein displaces endothelial nitric-oxide synthase (eNOS) from plasmalemmal caveolae and impairs eNOS activation. J Biol Chem. 1999;274:32512-32519.
34. Bist A, Fielding PE, Fielding CJ. Two sterol regulatory element-like sequences mediate up-regulation of caveolin gene transcription in response to low density lipoprotein free cholesterol. Proc Natl Acad Sci U S A. 1997;94: 10693-10698.
35. MRC/BHF Heart Protection Study of cholesterol lowering with simvastatin in 20,536 high-risk individuals: a randomised placebo-controlled trial. Lancet. 2002;360:7-22.
36. Sacks FM, Pfeffer MA, Moye LA, et al. The effect of pravastafin on coronary events after myocardial infarction in patients with average cholesterol levels. Cholesterol and Recurrent Events Trial investigators. N Engl J Med. 1996; 335:1001-1009.
37. Prevention of cardiovascular events and death with pravastatin in patients with coronary heart disease and a broad range of initial cholesterol levels. The Long-Term Intervention with Pravastatin in Ischaemic Disease (LIPID) Study Group. N Engl J Med. 1998;339:1349-1357.
38. Abetel G, Poget PN, Bonnabry JP. Hypotensive effect of an inhibitor of cholesterol synthesis (fluvastafin): a pilot study [in French]. Schweiz Med Wochenschr. 1998;128:272-277.
39. Borghi C, Prandin MG, Costa FV, et al. Use of stafins and blood pressure control in treated hypertensive patients with hypercholesterolemia. J Cardiovasc Pharmacol. 2000;35:549-555.
40. Riahi S, Christensen JH, Toft E, et al. HMG-CoA reductase inhibitors improve heart rate variability in patients with a previous myocardial infarction. Pharmacol Res. 2002;45:479-483.
41. Maggioni AP. Debate: should statin be used in patients with heart failure? Curr Control Trials Cardiovasc Med. 2001;2:266-267.